ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities Class Action - GSK
Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of GSK plc (NYSE: GSK) between February 5, 2020 and August 14, 2022, both dates inclusive ...
FiercePharma22h
PMCPA brings the buzzkill to LinkedIn celebration, laying into GSK over employee’s clicks
The PMCPA has turned party pooper, coming down on GSK after learning that a U.K. employee celebrated a post about a ...
GSK SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that GSK plc Shareholders Have Opportunity to Lead Class Action Lawsuit!
NEW YORK CITY, NY / ACCESS Newswire / February 21, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law ...
GSK’s Sluggish Shares Seen at Risk of New Activist Campaign
GSK Plc is a long-term underperformer among Europe’s Big Pharma stocks. And with key drug patents set to expire and vaccine ...
Ionis Continues to Expand Its Cardiology and Neurology Portfolio, Supporting Narrow Moat
Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...
C&EN2d
Long COVID studies stymied by pharma’s lack of cooperation
Pembrolizumab is a checkpoint inhibitor that binds to the protein PD-1 on T cells to help them recognize and attack invaders.
Medscape2d
Vasculitis Patients Need Multiple COVID Vaccine Boosters
Multiple vaccine shots are needed to boost vasculitis patients’ immunity against COVID, especially if they have been treated ...
labiotech3d
T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments
Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.
Medindia4d
Benign Prostatic Hyperplasia Surgical Treatment Market to Hit USD 17.19 Billion by 2030 with 5.3% CAGR | MarketsandMarkets™
The global Benign Prostatic Hyperplasia Surgical Treatment market, valued at US$11.92 billion in 2023, is forecasted to grow at a robust CAGR of 5.3%, reaching US$12.62 billion in 2024 and an ...
Valeo Financial Advisors LLC Sells 3,907 Shares of GSK plc (NYSE:GSK)
Valeo Financial Advisors LLC lowered its position in GSK plc (NYSE:GSK – Free Report) by 31.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and ...